ロード中...
Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospi...
保存先:
| 出版年: | ESC Heart Fail |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5542731/ https://ncbi.nlm.nih.gov/pubmed/28772041 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12179 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|